Final Data Analysis for Omacetaxine in Chronic, Accelerated Phase Chronic Myeloid Leukemia
the Cancer Therapy Advisor take:
Patients with chronic phase or accelerated phase chronic myeloid leukemia that is resistant and/or intolerant to two or more tyrosine kinase inhibitors can currently receive omacetaxine, a protein synthesis inhibitor.
The final analysis of omacetaxine, which included 24 months of follow-up, revealed additional safety and efficacy information to demonstrate the benefit of long-term omacetaxine administration in patients with chronic phase or accelerated phase chronic myeloid leukemia who received more than 3 cycles of treatment (1.25 mg/m2 twice daily for 14 days every 28 days followed by 7 days every 28 days).
The data showed that 18% of patients with chronic phase chronic myeloid leukemia achieved a major cytogenetic response that lasted a median of 12.5 months. The responses lasted for 12 months or more in three of 14 responders, and the rate of overall survival was a media of 40.3 months (95% CI, 23.8 months to NR). In patients with accelerated phase chronic myeloid leukemia, 14% of patients had a major hematologic response for a median of 4.7 months (95% CI, 3.6 months to NR).
In patients with accelerated phase chronic myeloid leukemia a major cytogenetic response was not seen and there was a median overall survival of 14.3 months (95% CI, 6.7, 18.7 months). There were 50 patients with chronic phase chronic myeloid leukemia who received more than 3 cycles of treatment and 14 patients with accelerated phase chronic myeloid leukemia who received more than 3 cycles of treatment. The median overall survival in these groups were 49.3 months (95% CI, 23.8 months to not reached) and 24.6 months (95% CI, 12, 37.2 months), respectively.
The most prominent side effects were grade 3 or higher hematologic toxicities (79% and 73% for chronic phase chronic myeloid leukemia and accelerated phase chronic myeloid leukemia, respectively). Ten percent of patients with chronic phase disease discontinued treatment because of toxicity and 5% of accelerated phase patients discontinued treatment because of toxicity.
Patients with chronic myeloid leukemia that is resistant to two or more tyrosine kinase inhibitors can currently receive omacetaxine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia